Key milestones for MGC Pharmaceuticals in 2019 include the launch of CannEpil sales in Australia, finalising contracts for the construction of a cannabis production and cultivation facility in Malta, and initiation of a Phase II study of CogniCann in dementia. The company has completed the sale of MGC Derma to CannaGlobal, which was announced in September. The transaction was restructured in November, which sees us reduce our valuation of the consideration to A$7.5m (vs A$12.5m). We adjust ou
04 Mar 2019
MGC Pharmaceuticals - MGC Derma sale completed
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MGC Pharmaceuticals - MGC Derma sale completed
Argent Biopharma Ltd (RGT:ASX) | 0 0 0.0% | Mkt Cap: 113.7m
- Published:
04 Mar 2019 -
Author:
Dr Dennis Hulme -
Pages:
7
Key milestones for MGC Pharmaceuticals in 2019 include the launch of CannEpil sales in Australia, finalising contracts for the construction of a cannabis production and cultivation facility in Malta, and initiation of a Phase II study of CogniCann in dementia. The company has completed the sale of MGC Derma to CannaGlobal, which was announced in September. The transaction was restructured in November, which sees us reduce our valuation of the consideration to A$7.5m (vs A$12.5m). We adjust ou